恩格列净在2型糖尿病合并慢性肾脏病患者中的安全性:安慰剂对照临床试验的汇总分析
该分析汇总19项随机安慰剂对照1-4期临床试验及1项扩展研究,评估恩格列净10 mg或25 mg每日一次在2型糖尿病合并中重度慢性肾脏病(G3-4)患者中的安全性。结果显示严重不良事件、导致停药的不良事件及特殊关注事件在恩格列净与安慰剂间相似,高钾血症和水肿风险在恩格列净组较低。
要点
- 在G3B/G4合并组和G3A组中,恩格列净与安慰剂的高钾血症风险分别为HR 0.59(95%CI 0.37-0.96,P=0.0323)和HR 0.48(95%CI 0.26-0.91,P=0.0243)。
- 在G3B/G4合并组和G3A组中,恩格列净与安慰剂的水肿风险分别为HR 0.47(95%CI 0.33-0.68,P<0.0001)和HR 0.44(95%CI 0.28-0.68,P=0.0002)。
- 严重不良事件、导致停药的不良事件及特殊关注事件(包括下肢截肢和急性肾衰竭)在恩格列净与安慰剂间相似。
核心结论
- 在2型糖尿病合并晚期慢性肾脏病患者中使用恩格列净未提出新的安全性问题,并可能对高钾血症和水肿的发生有益。
研究设计与样本
- 汇总19项随机、安慰剂对照、1-4期临床试验和1项随机、安慰剂对照扩展研究,患者接受恩格列净10 mg或25 mg每日一次。
- 共15,081例患者接受至少一剂研究药物,基线时分别有1,522例、722例和123例被分类为G3A、G3B和G4期慢性肾脏病。
主要发现
- 严重不良事件、导致停药的不良事件及特殊关注事件(包括下肢截肢和急性肾衰竭)的发生率在恩格列净与安慰剂间跨慢性肾脏病亚组相似。
- 在调整Cox回归分析中,G3B和G4合并组及G3A组中,恩格列净与安慰剂的容量不足和急性肾衰竭风险相似。
- 在G3B和G4合并组及G3A组中,恩格列净与安慰剂相比高钾血症风险分别为HR 0.59(95%CI 0.37-0.96,P=0.0323)和HR 0.48(95%CI 0.26-0.91,P=0.0243)。
- 在G3B和G4合并组及G3A组中,恩格列净与安慰剂相比水肿风险分别为HR 0.47(95%CI 0.33-0.68,P<0.0001)和HR 0.44(95%CI 0.28-0.68,P=0.0002)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the safety of empagliflozin in patients with type 2 diabetes and moderate to severe chronic kidney disease (CKD) (category G3-4) enrolled in clinical trials. RESEARCH DESIGN AND METHODS: This analysis pooled data from 19 randomized, placebo-controlled, phase 1-4 clinical trials and 1 randomized, placebo-controlled extension study in which patients received empagliflozin 10 mg or 25 mg daily. Time to first occurrence of adverse events (AEs) was evaluated using Kaplan-Meier analysis and multivariable Cox regression models. RESULTS: Among a total of 15,081 patients who received at least one study drug dose, 1,522, 722, and 123 were classified as having G3A, G3B, and G4 CKD, respectively, at baseline. Demographic and clinical characteristics were similar between treatment groups across CKD categories. Rates of serious AEs, AEs leading to discontinuation, and events of special interest (including lower limb amputations and acute renal failure [ARF]) were also similar between empagliflozin and placebo across CKD subgroups. In adjusted Cox regression analyses, risks for volume depletion and ARF were similar for empagliflozin and placebo in the combined group with CKD categories G3B and G4 and the G3A group. Notably lower risks were observed in both groups for hyperkalemia (hazard ratio 0.59 [95% CI 0.37-0.96, P = 0.0323] and 0.48 [0.26-0.91, P = 0.0243], respectively) and edema (0.47 [0.33-0.68, P < 0.0001] and 0.44 [0.28-0.68, P = 0.0002], respectively). CONCLUSIONS: Use of empagliflozin in patients with type 2 diabetes and advanced CKD raised no new safety concerns and may have beneficial effects on the development of hyperkalemia and edema.
引用
- Tuttle KR, Levin A, Nangaku M, et al. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care. 2022. PMID: 35472672. doi:10.2337/dc21-2034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。